ORIC Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
ORIC Pharmaceuticals has a total shareholder equity of $224.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $252.0M and $27.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$208.19m |
| Equity | US$224.09m |
| Total liabilities | US$27.92m |
| Total assets | US$252.01m |
Recent financial health updates
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24Recent updates
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01
Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Financial Position Analysis
Short Term Liabilities: ORIC's short term assets ($212.6M) exceed its short term liabilities ($20.5M).
Long Term Liabilities: ORIC's short term assets ($212.6M) exceed its long term liabilities ($7.5M).
Debt to Equity History and Analysis
Debt Level: ORIC is debt free.
Reducing Debt: ORIC has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORIC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ORIC has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 23.8% each year.